- Home
- NVCR
NVCR
NovoCure Limited
as of 03-12-2026 3:45pm EST
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
| Founded: | 2000 | Country: | Switzerland |
| Employees: | N/A | City: | ST. HELIER |
| Market Cap: | 1.5B | IPO Year: | 2015 |
| Target Price: | $28.08 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.22 | EPS Growth: | 21.79 |
| 52 Week Low/High: | $9.82 - $20.48 | Next Earning Date: | 05-20-2026 |
| Revenue: | $655,353,000 | Revenue Growth: | 8.28% |
| Revenue Growth (this year): | 7.72% | Revenue Growth (next year): | 6.74% |
| P/E Ratio: | -10.34 | Index: | N/A |
| Free Cash Flow: | -75679000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of NovoCure Limited (NVCR)
Chief Operating Officer
Avg Cost/Share
$13.77
Shares
43,246
Total Value
$595,670.40
Owned After
72,832
SEC Form 4
Chf Medical and Innovation Ofr
Avg Cost/Share
$13.31
Shares
6,412
Total Value
$85,314.22
Owned After
267,190
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$13.31
Shares
5,607
Total Value
$74,603.38
Owned After
493,793
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$13.31
Shares
1,100
Total Value
$14,635.94
Owned After
201,322
SEC Form 4
Former Chief Medical Officer
Avg Cost/Share
$13.31
Shares
1,100
Total Value
$14,635.94
Owned After
102,979
SEC Form 4
Chief Operating Officer
Avg Cost/Share
$13.31
Shares
5,377
Total Value
$71,543.14
Owned After
72,832
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$13.31
Shares
6,412
Total Value
$85,314.22
Owned After
182,842
SEC Form 4
Executive Chairman
Avg Cost/Share
$13.11
Shares
71,887
Total Value
$932,883.38
Owned After
349,727
Chf Medical and Innovation Ofr
Avg Cost/Share
$13.33
Shares
3,272
Total Value
$43,606.93
Owned After
267,190
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$13.49
Shares
7,232
Total Value
$97,581.38
Owned After
493,793
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Paravasthu Mukund | NVCR | Chief Operating Officer | Mar 5, 2026 | Sell | $13.77 | 43,246 | $595,670.40 | 72,832 | |
| Weinberg Uri | NVCR | Chf Medical and Innovation Ofr | Mar 4, 2026 | Sell | $13.31 | 6,412 | $85,314.22 | 267,190 | |
| Leonard Frank X | NVCR | Chief Executive Officer | Mar 4, 2026 | Sell | $13.31 | 5,607 | $74,603.38 | 493,793 | |
| Puri Michal Nath | NVCR | Chief Human Resources Officer | Mar 4, 2026 | Sell | $13.31 | 1,100 | $14,635.94 | 201,322 | |
| Leupin Nicolas | NVCR | Former Chief Medical Officer | Mar 4, 2026 | Sell | $13.31 | 1,100 | $14,635.94 | 102,979 | |
| Paravasthu Mukund | NVCR | Chief Operating Officer | Mar 4, 2026 | Sell | $13.31 | 5,377 | $71,543.14 | 72,832 | |
| Brackmann Christoph | NVCR | Chief Financial Officer | Mar 4, 2026 | Sell | $13.31 | 6,412 | $85,314.22 | 182,842 | |
| DOYLE WILLIAM F | NVCR | Executive Chairman | Mar 3, 2026 | Sell | $13.11 | 71,887 | $932,883.38 | 349,727 | |
| Weinberg Uri | NVCR | Chf Medical and Innovation Ofr | Mar 2, 2026 | Sell | $13.33 | 3,272 | $43,606.93 | 267,190 | |
| Leonard Frank X | NVCR | Chief Executive Officer | Mar 2, 2026 | Sell | $13.49 | 7,232 | $97,581.38 | 493,793 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 26, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 26, 2026 · 100% conf.
1D
-2.44%
$13.41
5D
-6.57%
$12.85
20D
-10.02%
$12.37
nvcr-202602260001645113false00016451132026-02-012026-02-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
February 26, 2026 Date of Report (date of earliest event reported)
NovoCure Limited (Exact name of registrant as specified in its charter)
Jersey 001-3756598-1057807
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street St. Helier Jersey
JE2 4UF
(Address of Principal Executive Offices) (Zip Code)
+44 (0) 15 3475 6700 Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On February 26, 2026, the Company issued a press release announcing certain financial results for the fiscal year and quarter ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1Press Release of NovoCure Limited, dated February 26, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited (Registrant)
Date: February 26, 2026
By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
1D
-2.44%
$13.41
5D
-6.57%
$12.85
20D
-10.02%
$12.37
nvcr-202601120001645113false00016451132026-01-012026-01-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
January 12, 2026 Date of Report (date of earliest event reported)
NovoCure Limited (Exact name of registrant as specified in its charter)
Jersey 001-3756598-1057807
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street St. Helier Jersey
JE2 4UF
(Address of Principal Executive Offices) (Zip Code)
+44 (0) 15 3475 6700 Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On January 12, 2026, NovoCure Limited ( the "Company") issued a press release announcing certain preliminary financial results and providing certain other information for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 (the “Press Release”).
The financial data contained therein are unaudited, preliminary, based upon the Company’s good faith estimates and subject to completion of the Company’s financial closing procedures. While the Company expects that its final financial results for the quarter and year ended December 31, 2025, following the completion of its financial closing procedures, will generally be consistent with the information provided in the Press Release, the Company’s actual results may differ materially from these estimates as a result of the completion of its financial closing procedures for the quarter and year ended December 31, 2025, as well as final adjustments and other developments that may arise between now and the time that its financial results for the quarter and year ended December 31, 2025 are finalized.
The information contained in item 2.02 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1Press Release of NovoCure Limited, dated January 12, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited (Registrant)
Date: January 12, 2026
By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 30, 2025
Q3 2025 Earnings
8-KOct 30, 2025
nvcr-202510300001645113false00016451132025-07-162025-10-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
October 30, 2025 Date of Report (date of earliest event reported)
NovoCure Limited (Exact name of registrant as specified in its charter)
Jersey 001-3756598-1057807
(State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.)
No. 4 The Forum, Grenville Street St. Helier Jersey
JE2 4UF
(Address of Principal Executive Offices) (Zip Code)
+44 (0) 15 3475 6700 Registrant's telephone number, including area code
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered Ordinary Shares, no par valueNVCRThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On October 30, 2025, the Company issued a press release announcing certain financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1Press Release of NovoCure Limited, dated October 30, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NovoCure Limited (Registrant)
Date: October 30, 2025
By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer
Compare NVCR vs Leading Stocks
See how NVCR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NVCR NovoCure Limited - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.